GlassScriptPhysician profile
Bassam E Haddad
NPI 1790949790
$2,692.52
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.26 · 2021: $1,186 · 2022: $914 · 2023: $536 · 2024: $13.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $796.09 | 2020-2023 | Relistor |
| Forte Bio-Pharma LLC | $585.23 | 2020-2023 | Prolate, Nalocet |
| Kowa Pharmaceuticals America, INC. | $190.45 | 2022-2023 | Seglentis, Livalo |
| Medtronic, INC. | $158.33 | 2021-2022 | |
| Abbott Laboratories | $129.60 | 2021 | |
| Virtus Pharmaceuticals LLC | $125.47 | 2021 | |
| Collegium Pharmaceutical, INC. | $113.71 | 2021-2022 | |
| Uswm, LLC | $103.01 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $77.13 | 2022 | |
| Horizon Therapeutics Plc | $68.48 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $63.01 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $52.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.50 | 2023-2024 | Ofev, Jardiance |
| Abbvie INC. | $45.77 | 2022-2023 | |
| Redhill Biopharma INC. | $29.50 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $22.97 | 2022 | |
| Gilead Sciences, INC. | $22.83 | 2023 | |
| Alnylam Pharmaceuticals INC. | $22.67 | 2023 | Onpattro |
| Biodelivery Sciences International, INC. | $17.94 | 2021 | |
| Grt US Holding, INC. | $16.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassam Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.